Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Plunged in September

By George Budwell – Updated Oct 6, 2021 at 10:35AM

Key Points

  • Novavax's COVID-19 vaccine has yet to earn an EUA from the FDA.
  • Newly developed oral COVID-19 treatments, while not approved yet, have been hurting vaccine stocks.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Two key pressures weighed on the biotech's stock.

What happened

Shares of Novavax (NVAX -2.88%) fell by an eye-catching 17.7% in September, according to data provided by S&P Global Market Intelligence. The vaccine specialist's shares have been locked into a multi-month downward trend of late for a variety of reasons. 

Chief among those reasons, Novavax has yet to earn an Emergency Use Authorization (EUA) in the U.S. for its COVID-19 vaccine candidate, NVX-CoV2373 -- a hurdle it originally expected to have cleared in May. The biotech now says it plans to file for an EUA with the Food and Drug Administration by the end of the year.

Meanwhile, Pfizer (PFE 0.74%), BioNTech, and Moderna have been racking up tens of billions of dollars in sales for their respective COVID-19 vaccines this year. Novavax, in short, is missing out on the party. 

A patient getting a vaccine in a clinic.

Image source: Getty Images.

So what

Another major problem facing the company is that several pandemic experts, and even some top biopharma companies like Pfizer and Roche, have started to suggest that the acute phase of the pandemic could be over within the next 12 months. Novavax's experimental COVID-19 vaccine, therefore, may have a shorter-than-expected commercial shelf life.

Now, Novavax's vaccine is still likely to do fairly well, sales-wise, internationally in markets such as India, Indonesia, and the Philippines past 2022. But there's no way to tell how it will fare in markets like Canada and the United States, where options are more abundant, once the acute phase of the pandemic comes to an end.

Complicating matters further, Atea Pharmaceuticals, Merck, Pfizer, and others may all apply for regulatory approval for their oral COVID-19 antiviral treatments within the next six months. These easy-to-use pills may be taken by patients at home in some cases, and effective treatments for the coronavirus might further erode the demand for COVID-19 vaccines.   

Now what

Is Novavax's stock worth buying on this prolonged slide? Over the past 90 days, the biotech's shares have fallen by more than 22%. That's not surprising with Pfizer and Moderna dominating the vaccine market in the U.S. and Merck's oral COVID-19 medication showing promise in late-stage trials. Novavax's main share-price driver over the past year, after all, has been the commercial promise of NVX-CoV2373. 

Novavax's stock could certainly rebound. There's no guarantee that these oral medications will turn out to be safe enough to use in a home setting, and there remains the possibility that new variants might require another global vaccination effort. All that being said, there are scores of other biotech stocks that arguably sport more compelling risk-to-reward ratios than Novavax's right now. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Atea Pharmaceuticals, Inc. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax Stock Quote
Novavax
NVAX
$16.54 (-2.88%) $0.49
Pfizer Stock Quote
Pfizer
PFE
$49.21 (0.74%) $0.36
Roche Holding Ltd. (ADR) Stock Quote
Roche Holding Ltd. (ADR)
RHHBY
$41.06 (1.08%) $0.44
Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$176.40 (-0.23%) $0.41
BioNTech SE Stock Quote
BioNTech SE
BNTX
$154.85 (-0.88%) $-1.38
Atea Pharmaceuticals, Inc. Stock Quote
Atea Pharmaceuticals, Inc.
AVIR
$4.69 (%)

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.